The role of Brd4 in Tet2 deficient clonal hematopoiesis
Description: Acute myeloid leukemia (AML) is a cancer of the blood forming stem cells in the bone marrow. While AML can be diagnosed at any age, including in childhood, it is generally a disease of the elderly, with the average age at diagnosis being 68. With current treatments, the prognosis of AML is poor. Only approximately 20% of AML patients will survive 5 years after diagnosis, with prognosis being worse in those over the age of 60. Scientists have recently recognized that it is common for the cells of the bone marrow to acquire genetic changes, or mutations, with age. Up to 15% of elderly individuals have detectable mutations in their bone marrow, a condition termed clonal hematopoiesis. While most people with clonal hematopoiesis have no symptoms, they are at increased risk of developing AML and other cancers of the blood. Clonal hematopoiesis is therefore considered a pre-cancerous state. Mutations associated with clonal hematopoiesis alter white blood cell function so that there is increased inflammation in the body. It is believed that this inflammation can cause progression to AML by promoting additional genetic changes in the bone marrow. As more changes accumulate, cells become more abnormal, eventually becoming cancerous. Unfortunately, we do not currently have any way of preventing the progression from clonal hematopoiesis to leukemia.
The goals of this project are to understand how acute myeloid leukemia (AML) develops from pre-cancerous states and how a class of drugs called BET inhibitors might be used to prevent leukemia. The Tet2 gene is frequently mutated in clonal hematopoiesis and in AML. Our lab uses mice that have been genetically engineered to have mutated Tet2 genes. These animals model a pre-leukemic state, since their bone marrow stem cells divide more often. In addition, similar to humans with clonal hematopoiesis, these mice have increased inflammation in their bodies. With age they develop an increased number of white blood cells in the blood. It is believed that the increased inflammation is required for development of leukemia in these mice. One gene called Brd4 is known to be important for the inflammation produced by white blood cells. Importantly, the activity of Brd4 can be blocked by a class of drugs called BET inhibitors. In this project, mice which lack the Brd4 gene are bred with Tet2 mutant mice. The goal is to see if the absence of Brd4 reduces the inflammation and white blood cell count in the mice and prevents development of leukemia. In other experiments, Tet2 mutant mice are given a BET inhibitor drug to determine if 1) this reduces the inflammation known to drive Tet2 mutant mice to develop leukemia and 2) development of leukemia is reduced or delayed. If this research is successful, it would demonstrate that BET inhibitors prevent progression to leukemia from a pre-leukemic state. This would support additional clinical research to see if BET inhibitors can also prevent leukemia in people.
Funder: American Cancer Society
Amount: $583,000
Funding type: award
Start date: 2023-01-01
End date: 2027-12-31
Investigator: Nicole Grieselhuber (lead)
Institution: The Ohio State University
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: CSDG-22-866350-01-IBCD
OpenAlex ID: G3764658369
